当前位置: X-MOL 学术ACS Med. Chem. Lett. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
SAR Studies of N-[2-(1H-Tetrazol-5-yl)phenyl]benzamide Derivatives as Potent G Protein-Coupled Receptor-35 Agonists
ACS Medicinal Chemistry Letters ( IF 3.5 ) Pub Date : 2018-04-09 00:00:00 , DOI: 10.1021/acsmedchemlett.7b00510
Lai Wei 1, 2 , Tao Hou 1 , Chang Lu 1, 2 , Jixia Wang 1 , Xiuli Zhang 1, 3 , Ye Fang 4 , Yaopeng Zhao 1 , Jiatao Feng 1 , Jiaqi Li 1, 2 , Lala Qu 1, 2 , Hai-long Piao 1 , Xinmiao Liang 1, 3
Affiliation  

G protein-coupled receptor-35 (GPR35) has emerged as a potential target in the treatment of pain and inflammatory and metabolic diseases. We have discovered a series of potent GPR35 agonists based on a coumarin scaffold and found that the introduction of a 1H-tetrazol-5-yl group significantly increased their potency. We designed and synthesized a new series of N-[2-(1H-tetrazol-5-yl)phenyl]benzamide derivatives through a two-step synthetic approach, and characterized their agonistic activities against GPR35 using a dynamic mass redistribution (DMR) assay. N-(5-bromo-2-(1H-tetrazol-5-yl)phenyl)-4-methoxybenzamide (56) and N-(5-bromo-2-(1H-tetrazol-5-yl)phenyl)-2-fluoro-4-methoxybenzamide (63) displayed the highest agonistic potency agonist GPR35 with an EC50 of 0.059 μM and 0.041 μM, respectively. The physicochemical properties of selected compounds were calculated to evaluate their druglikeness, suggesting that compounds 56 and 63 have good druglike properties. Together, N-[2-(1H-tetrazol-5-yl)phenyl]benzamide derivatives are potentially great candidates for developing potent GPR35 agonists.

中文翻译:

N- [2-(1H-替硝唑-5-基)苯基]苯甲酰胺衍生物作为强G蛋白偶联受体35激动剂的SAR研究

G蛋白偶联受体35(GPR35)已成为治疗疼痛,炎性和代谢性疾病的潜在靶标。我们已经发现了一系列基于香豆素骨架的强效GPR35激动剂,并发现引入1 H-四唑-5-基大大提高了它们的效价。我们通过两步合成方法设计和合成了一系列新的N- [2-(1 H-四唑-5-基)苯基]苯甲酰胺衍生物,并使用动态质量重新分配(DMR)表征了它们对GPR35的激动活性。分析。N-(5-溴-2-(1 H-四唑-5-基)苯基)-4-甲氧基苯甲酰胺(56)和N-(5-溴-2-(1 H-四唑-5-基)苯基)-2-氟-4-甲氧基苯甲酰胺(63)显示出最高的激动剂激动剂GPR35,EC 50分别为0.059μM和0.041μM 。计算了所选化合物的理化性质,以评估其药物相似性,表明化合物5663具有良好的药物相似性能。一起,Ñ - [2-(1H-四唑-5-基)苯基]苯甲酰胺衍生物是潜在地用于开发有效的GPR35激动剂大候选。
更新日期:2018-04-09
down
wechat
bug